Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 What's new in FGF23 research?

Literature DB >> 23951494

What's new in FGF23 research?

Abstract

FGF23 is a hormone that regulates phosphate and vitamin D metabolism by binding to Klotho-fibroblast growth factor (FGF) receptor complex. Excess actions of FGF23 cause several kinds of hypophosphatemic diseases. The mechanism of overproduction of FGF23 in some of these diseases is becoming clear, whereas it is not yet completely understood. Several specific methods to inhibit FGF23 actions have been reported as candidates for new therapies for these FGF23-related hypophosphatemic diseases. On the other hand, many epidemiological studies indicated the association between high FGF23 levels and several adverse events in cardiovascular system, kidney, bone and mortality. FGF23 was recently shown to induce ventricular hypertrophy in a Klotho-independent manner. However, it is not yet shown whether this Klotho-independent action of FGF23 can explain all the results of epidemiological studies.

Entities: Chemical Disease Gene

Year: 2012 PMID： 23951494 PMCID： PMC3727838 DOI： 10.1038/bonekey.2012.111

Source DB: PubMed Journal: Bonekey Rep ISSN： 2047-6396

34 in total

1. FGF-23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease-mineral bone disorder and the heart.

Authors: Martin L Ford; Edward R Smith; Laurie A Tomlinson; Prabal K Chatterjee; Chakravarthi Rajkumar; Stephen G Holt
Journal: Nephrol Dial Transplant Date: 2011-07-12 Impact factor: 5.992

2. Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans.

Authors: Erik A Imel; Munro Peacock; Amie K Gray; Leah R Padgett; Siu L Hui; Michael J Econs
Journal: J Clin Endocrinol Metab Date: 2011-08-31 Impact factor: 5.958

3. Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis.

Authors: Chikako Nakano; Takayuki Hamano; Naohiko Fujii; Yoshitsugu Obi; Isao Matsui; Kodo Tomida; Satoshi Mikami; Kazunori Inoue; Akihiro Shimomura; Yasuyuki Nagasawa; Noriyuki Okada; Yoshiharu Tsubakihara; Hiromi Rakugi; Yoshitaka Isaka
Journal: Bone Date: 2012-03-06 Impact factor: 4.398

Review 4. Fibroblast growth factor 23 as a phosphotropic hormone and beyond.

Authors: Seiji Fukumoto; Yuichiro Shimizu
Journal: J Bone Miner Metab Date: 2011-08-06 Impact factor: 2.626

5. Inorganic phosphate and FGF-23 predict outcome in stable systolic heart failure.

Authors: Max Plischke; Stephanie Neuhold; Christopher Adlbrecht; Bernhard Bielesz; Sascha Shayganfar; Christian Bieglmayer; Thomas Szekeres; Walter H Hörl; Guido Strunk; Patrick Vavken; Richard Pacher; Martin Hülsmann
Journal: Eur J Clin Invest Date: 2011-12-13 Impact factor: 4.686

6. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis.

Authors: Jessica Kendrick; Alfred K Cheung; James S Kaufman; Tom Greene; William L Roberts; Gerard Smits; Michel Chonchol
Journal: J Am Soc Nephrol Date: 2011-09-07 Impact factor: 10.121

7. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23.

Authors:
Journal: Nat Genet Date: 2000-11 Impact factor: 38.330

8. Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling.

Authors: Aline Martin; Shiguang Liu; Valentin David; Hua Li; Anastasios Karydis; Jian Q Feng; L Darryl Quarles
Journal: FASEB J Date: 2011-04-20 Impact factor: 5.191